Evidence map›Paper›PMID 20438378›Full record

Trial reportAIDS patient care and STDs2010

Disparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial.

Thomas P Giordano, Glenn Bartsch, Yafeng Zhang, Ellen Tedaldi, Judith Absalon, Sharon Mannheimer, Avis Thomas, Rodger D MacArthur

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in AIDS patient care and STDs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03331978 (A Randomized Controlled Trial of an Antiretroviral Treatment Adherence Intervention for HIV+ African Americans), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03331978 nacompletednot on this mapstarted 2018, after this paper: background citation

A Randomized Controlled Trial of an Antiretroviral Treatment Adherence Intervention for HIV+ African Americans

TypeinterventionalSponsorRANDRan2018 to 2021Enrolled306ConditionsHIV/AIDSArmsRise - Treatment Education
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Antiretroviral Therapy: Racial Disparities among Publicly Insured Californians with HIV.Journal of health care for the poor and underserved · 2017
    Article
  7. Article
  8. Article
  9. Article
  10. The Effect of Structural Violence on Patients with Sickle Cell Disease.Journal of health care for the poor and underserved · 2015
    Article
  11. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
    Article
  12. Article
  13. Article
  14. The Hispanic HIV Epidemic.Current infectious disease reports · 2013
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Thomas P GiordanoBaylor College of Medicine, Michael E. DeBakey VA Medical Center, and Thomas Street Health Center, Houston, Texas 77030, USA. tpg@bcm.tmc.edu
Glenn Bartsch
Yafeng Zhang
Ellen Tedaldi
Judith Absalon
Sharon Mannheimer
Avis Thomas
Rodger D MacArthur

Funding

COMMUNITY PROGRAMS FOR CLINICAL RESEARCH ON AIDSU01AI046362 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI GORDIN, FRED M · 2000 to 2006
$75.9M
TERRY BEIRN COMMUNITY PROGRAMS FOR CLINICAL RESEARCH ONU01AI042170 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI NEATON, JAMES DENNIS · 1997 to 2006
$23.2M
HIV,Race and Survival in the Highly Active Therapy EraK23MH067505 · NIMH · BAYLOR COLLEGE OF MEDICINE · PI GIORDANO, THOMAS P · 2003 to 2007
$896k
NIAID NIH HHS 5U01AI042170-10NIAID NIH HHS 5U01 AI046362-03NIMH NIH HHS K23MH067505
6 · The paper itself

Abstract

To benefit maximally from antiretroviral therapy, patients with HIV infection must enter care before their disease is advanced and adhere to care. We sought to determine if and where on this continuum of care racial/ethnic disparities were evident. Data from the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial, which evaluated three strategies for initial HIV therapy, were compared for White, African American, and Latino subjects. Outcomes included progression of disease and death, HIV viral suppression, and change in CD4(+) cell count. Multivariate Cox proportional hazard models adjusted for known predictors of survival. There were 1357 subjects, including 368 non-Latino white, 751 non-Latino African American, and 238 Latino subjects. At baseline, the two latter groups were more likely to have had AIDS and had lower CD4(+) cell counts than white subjects. In follow-up, African American subjects had lower self-reported adherence to therapy, lower CD4(+) cell count increases, and lower odds of viral suppression. African American and Latino subjects had unadjusted hazard ratios of progression of disease or death of 1.57 (1.17, 2.10; p = 0.0025) and 1.57 (1.09, 2.26; p = 0.02), respectively. Adjusting for baseline differences and differences in adherence, CD4(+) cell count change, and viral suppression accounted for the disparities in outcomes. Opportunities to reduce disparities in outcomes for African American and Latino patients exist along the continuum of HIV care. Efforts to promote access to HIV testing and care and to improve adherence have the potential to reduce racial/ethnic disparities in outcomes of patients with HIV infection.

Indexed as

Black or African AmericanHealthcare DisparitiesHispanic or LatinoAnti-HIV AgentsBlack PeopleCD4 Lymphocyte CountDisease ProgressionDrug Therapy, CombinationHealth Services AccessibilityHIV-1HIV InfectionsHumansMedication AdherenceReverse Transcriptase InhibitorsSurvival RateTreatment OutcomeAnti-HIV AgentsReverse Transcriptase Inhibitors

Identifiers

PMID20438378
PMCPMC2933555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.